loading page

Use of drugs with Pharmacogenomics (PGx)-Based Dosing Guidelines in a Danish Cohort of Persons with Chronic Kidney Disease, Both on Dialysis and Not on Dialysis: Perspectives for Prescribing Optimization
  • +3
  • Niels Westergaard,
  • Morten Baltzer Houlind,
  • Lona Christrup,
  • Helle Juul-Larsen,
  • Charlotte Strandhave,
  • Anne Estrup Olesen
Niels Westergaard
Professionshojskolen Absalon - Campus Roskilde

Corresponding Author:[email protected]

Author Profile
Morten Baltzer Houlind
Hvidovre Hospital
Author Profile
Lona Christrup
Kobenhavns Universitet Institut for Lagemiddeldesign og Farmakologi
Author Profile
Helle Juul-Larsen
Hvidovre Hospital
Author Profile
Charlotte Strandhave
Aalborg Universitetshospital
Author Profile
Anne Estrup Olesen
Aalborg Universitet Klinisk Institut
Author Profile


Aim: The objective of this registry study is to assess the utilization of PGx drugs among patients with CKD Methods: This study was a retrospective study of patients affiliated to the Department of Nephrology, Aalborg University Hospital, Denmark during 2021. Patients diagnosed with CKD were divided into CKD without dialysis and CKD with dialysis. PGx prescription drugs were retrieved from the Patient Administration System. Actionable dosing guidelines (AG) for specific drug-gene pairs for CYP2D6, CYP2C9, CYP2C19 and SLCO1B1were retrieved from the PharmGKB homepage. Results: Out of 1241 individuals, 25.5% were on dialysis. The median number of medications for each patient was 9 within the non-dialysis group, and 16 within the dialysis group. Thirty-one distinct PGx drugs were prescribed. Altogether, 76.0% (943 individuals) were prescribed at least 1 PGx drugs and the prevalence of prescriptions of PGx drugs was higher the dialysis group compared to the non-dialysis group. The most frequently prescribed drugs with AG were metoprolol, pantoprazole, atorvastatin, simvastatin, warfarin. Conclusion: This study demonstrated that a substantial proportion of patients with CKD are exposed to drugs or drug combinations for which there exists actionable dosing guidelines related to PGx of CYP2D6, CYP2C19, CYP2C9, and SLCO1B1.
22 Oct 2023Submitted to Basic & Clinical Pharmacology & Toxicology
23 Oct 2023Assigned to Editor
23 Oct 2023Submission Checks Completed
23 Oct 2023Review(s) Completed, Editorial Evaluation Pending
24 Oct 2023Reviewer(s) Assigned
21 Nov 2023Editorial Decision: Revise Major